EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial

Ming Liu iD, Weijun Gu, Li Chen iD, Yanbing Li iD, Hongyu Kuang, Jianling Du, Agustina Alvarez, Felipe Lauand, Elisabeth Souhami, Jiewen Zhang, Weiya Xu, Qin Du und 2 weitere

Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 3791-3800

DOI: 10.1111/dom.15724 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 22.06.2024. Verfasst von Ming Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glycated Hemoglobin, Hypoglycemic Agents, Insulin Glargine. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To compare the efficacy and safety of a fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with premixed insulin, insulin degludec plus insulin aspart (IDegAsp), in Chinese people with type 2 diabetes (T2D) suboptimally controlled with oral antidiabetic drug(s) (OADs).

Methods

In Soli‐D, a 24‐week, multicentre, open‐label, study, insulin‐naïve adults were randomized 1:1 to once‐daily injections of iGlarLixi ( n = 291) or IDegAsp ( n = 291), with continued metformin ± sodium‐glucose co‐transporter‐2 inhibitors. The primary endpoint was non‐inferiority in HbA1c change from baseline to week 24. Key secondary endpoints included superiority in HbA1c change and body weight (BW) change at week 24. Hypoglycaemia rates were also assessed.

Results

At week 24, iGlarLixi showed non‐inferiority and superiority over IDegAsp in HbA1c reduction (least squares [LS] mean difference: −0.20 [95% confidence interval {CI}: –0.33, −0.07]; P < .001 for non‐inferiority; [97.5% CI: –0.35, −0.05]; P = .003 for superiority). iGlarLixi decreased BW and IDegAsp increased BW from baseline to week 24, with a statistically significant LS mean difference of −1.49 kg in favour of iGlarLixi (97.5% CI: –2.32, −0.66; P < .001). Event rates (per person‐year) for American Diabetes Association (ADA) Level 1, 2 or 3 hypoglycaemia were lower for iGlarLixi (1.90) versus IDegAsp (2.72) (relative risk: 0.71; 95% CI: 0.52, 0.98). No ADA Level 3 hypoglycaemia or unexpected safety findings were reported.

Conclusions

In Chinese people with T2D suboptimally controlled with OADs, once‐daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glycated HemoglobinHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralBlood GlucoseChinaDrug CombinationsEast Asian PeopleGlucagon-Like Peptide-2 ReceptorHypoglycemiaMetforminPeptidesTreatment Outcome

Stichwörter der Autor:innen

Chinese populationbody weightfixed‐ratio combinationglucagon‐like peptide‐1 receptor agonistglycaemic controlhypoglycaemiaiGlarLixipremixed insulin

Substanzen

Blood GlucoseDrug CombinationsGlucagon-Like Peptide-2 ReceptorGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic Agentsinsulin degludec, insulin aspart drug combinationInsulin GlargineInsulin, Long-Actinglixisenatide

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Endocrinology, The First Medical Centre, Chinese People's Liberation Army General Hospital, Beijing, China.
  • Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.
  • Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Endocrinology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.

ORCID-Profile: Ming Liu, Li Chen, Yanbing Li, Yiming Mu

Förderung

  • Sanofi

Zitieren

APA

Liu, M., Gu, W., Chen, L., Li, Y., Kuang, H., Du, J., Alvarez, A., Lauand, F., Souhami, E., Zhang, J., Xu, W., Du, Q., Mu, Y., & SoliD trial investigators (2024). The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial. Diabetes, Obesity and Metabolism, 26(9), 3791-3800. https://doi.org/10.1111/dom.15724

Vancouver

Liu M, Gu W, Chen L, Li Y, Kuang H, Du J, et al. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial. Diabetes, Obesity and Metabolism. 2024;26(9):3791-3800. doi:10.1111/dom.15724

BibTeX
@article{Liu2024,
  author = {Liu, Ming and Gu, Weijun and Chen, Li and Li, Yanbing and Kuang, Hongyu and Du, Jianling and Alvarez, Agustina and Lauand, Felipe and Souhami, Elisabeth and Zhang, Jiewen and Xu, Weiya and Du, Qin and Mu, Yiming and SoliD trial investigators, SoliD trial investigators},
  title = {The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {9},
  pages = {3791--3800},
  doi = {10.1111/dom.15724}
}
Kostenlos starten →